Stocks
Allarity Therapeutics, Inc.ALLR
NASDAQHealthcareBiotechnology$0.87
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing personalized cancer therapies based on its drug response predictor technology. The company's lead candidate, dovitinib, targets multiple tumor types, and its proprietary DRP platform aims to identify patients most likely to respond to treatment. Investors track Allarity for its precision medicine approach and upcoming clinical data readouts.
52W Range: $0.77-$1.84
Congressional Interest in Allarity Therapeutics, Inc. (ALLR)
No congressional trades have been disclosed for Allarity Therapeutics, Inc. (ALLR) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ALLR?
No congressional trades found for this stock.